FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma

CompletedOBSERVATIONAL
Enrollment

480

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Lymphoma
Interventions
PROCEDURE

FDG PET/CT guided metabolic core needle biopsy

The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).

Trial Locations (1)

160012

Department of Nuclear Medicine, PGIMER, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT05186610 - FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma | Biotech Hunter | Biotech Hunter